Overview

A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the use of 2 different Prothrombin Complex Concentrates (PCCs) on their ability to reverse (normalize) the pharmacodynamic effects of rivaroxaban in healthy adult volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Bayer

Treatments:

Rivaroxaban
Thrombin